Some collaborations change the face of treatment scenario, and this collaboration is one example of that. An immunologist collaborated with an oncologist to help fight the immunologist’s stepmother fight cancer, and turned the face of transformative therapy. The discovery is of a new class of drugs that help in bypassing a molecular break that stops the immune system from attacking tumors. The main problem in cancer is that patients immunotherapy doesn’t always work. Here, the researchers identified a unique type of immune-system cell that helps in predicting whether patients will respond to one of the medicines or not—significantly sorting out patients that can positively benefit from the therapy. This discovery is based on the analysis of 40 patients, whose cancer is treated with Keytruda, a checkpoint inhibitor from Merck & Co., which targets an immune-system brake called PD-1.
DelveInsight Blog
Related Article

Immuno-Oncology (I-O) Therapeutics: The Key to Future Cancer Treatment
Oncology has become a growing area of interest for pharmaceutical companies over the years. With a significant increase in R&D and healthcare spending worldwide, companies ranging from large pharmaceutical conglomerates to smaller biotech organizations are frantically attempting to capitalize on lucrative marke...
Find More
Evaluating the Key Trends and Developments in the Global Next-Generation Sequencing Market
Next-Generation Sequencing (NGS) or commonly referred to as deep sequencing or massively parallel sequencing, is an important field of sequencing technology applied to determine the RNA or DNA sequence. It aims to provide detailed information about the genetic variation in organisms, diseases, or other biological p...
Find More
ASH 2022: Roche’s Polivy vs ADC Therapeutics’ Zynlonta, Antibody-Drug Conjugates (ADC) in R/R DLBCL
Blood cancers have seen tremendous advancements in the past few years owing to the dedication of the researchers who are putting their endless efforts just to bring innovation into the lives of suffering patients. These experimentations and their upshots are always brought to us through various platforms, the Ameri...
Find MoreEditor's Pick
Newsletter/Whitepaper
Recent Article
ASCO Conference 2023

The American Society of Clinical Oncology (ASCO) is one of the largest and most respected conferences in the field of oncology. Held annually, this conference brings together researchers, physicians, and other healthcare professionals from around the world to discuss the latest advances in cancer research, diagnosis, and treatment.